Testosterone transdermal - Warner Chilcott/Watson

Drug Profile

Testosterone transdermal - Warner Chilcott/Watson

Alternative Names: Intrinsa; Intrinsa CHF; Livensa; Testosterone transdermal TheraDerm MTX; WC3048; WC3049

Latest Information Update: 15 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Watson Laboratories
  • Developer Noven Pharmaceuticals; Procter & Gamble; Warner Chilcott; Watson Laboratories
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone congener stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Female sexual dysfunction
  • Suspended Heart failure
  • No development reported Hypogonadism
  • Discontinued Cachexia; Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 23 Jan 2015 Biomarkers information updated
  • 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
  • 05 Jul 2013 No development reported - Phase-II for Hypogonadism in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top